ARA 290 10mg

ARA 290 10mg
£35.00

(NOT FOR HUMAN CONSUMPTION RESEARCH USE ONLY) 

ARA 290 10mg

also known as Cibinetide or PHBSP, is an investigational synthetic peptide that is a non-hematopoietic analog of erythropoietin, primarily studied for its potent anti-inflammatory and tissue-protective effects, particularly in the treatment of neuropathic pain. 

 
Mechanism of Action 
ARA 290 works by selectively binding to and activating the innate repair receptor (IRR), a specific receptor complex (a heterocomplex of the erythropoietin receptor and the
β
𝛽
-common receptor) that is upregulated in response to tissue injury and inflammation. This activation initiates a signaling cascade that: 
  • Inhibits Apoptosis: Prevents programmed cell death in damaged tissues.
  • Modulates Inflammation: Down-regulates pro-inflammatory responses, effectively reprogramming the local environment from one of damage to one of healing.
  • Promotes Nerve Regeneration: Encourages neurite outgrowth (nerve regeneration) and can increase corneal nerve fiber density in patients with small fiber neuropathy.
  • Pain Relief: It has been shown to reduce neuropathic pain by targeting the IRR and potentially by inhibiting the TRPV1 pain-sensing channel activity. 
 
Clinical Research and Status 
ARA 290 has been the subject of several clinical trials, primarily for conditions involving nerve damage and chronic inflammation. 
  • Neuropathic Pain in Sarcoidosis: It was granted Orphan Drug Product designation by the FDA for the treatment of neuropathic pain in sarcoidosis patients. Clinical studies in these patients showed significant improvements in pain symptoms, functional capacity (like walking distance), and quality of life, with long-lasting effects even after treatment cessation.
  • Diabetic Neuropathy: Phase 2 studies in patients with type 2 diabetes and painful neuropathy indicated that ARA 290 improved both neuropathic symptoms and metabolic markers like hemoglobin A1c and lipid profiles.
  • Other Potential Uses: Research interest areas include traumatic brain injuries, cardiovascular diseases, and diabetic macular edema. 
 
Safety and Availability 
  • Safety Profile: Clinical trials have reported that ARA 290 is well-tolerated, with no significant adverse events or safety issues noted in patients receiving repeated doses over several weeks. It avoids the hematopoietic side effects (red blood cell production, high blood pressure, etc.) associated with full erythropoietin (EPO).
  • Availability: Currently, ARA 290 is an investigational compound and is not an FDA-approved prescription medication for general clinical use. It is available for purchase from various online retailers as a "research chemical" (for laboratory use only).